



## BioSerenity, digital health champion, raises 15 million Euros

**Paris, September 20<sup>th</sup> 2017 - Start-up specialized in connected solutions for patients, BioSerenity closed a Series A round of €15 million led by LBO France and investments from Idinvest Partners and PSIM fund managed by Bpifrance.**

BioSerenity has developed several product lines to facilitate the diagnosis and monitoring of patients. The high growth medtech company collaborated with several large scale university hospitals across the globe and plans on leveraging the new round of financing to continue its industrialization, and internationalization. With over 80 employees, BioSerenity has recently opened new offices in France, China and the United-States.


BioSerenity offers disease specific full-stack solutions to speed up diagnosis, facilitate the follow-up and help calibrate treatments. The company currently focuses on 4 main pathological areas : Epilepsy, Cardiovascular diseases, Pregnancy monitoring and Sleep disorders.

BioSerenity has successfully deployed a collaborative business model with the pharmaceutical industry through partnerships that rely on the creation of a complete technological solution (hardware device, smartphone app, medical cloud, and an automatic analysis of data by Artificial Intelligence). Each partnership is centered around a disease area in which the pharmaceutical company is specialized.

The pharmaceutical companies use their global reach to deploy the solution around the world and take advantage of the devices for their own clinical trials or companion diagnostics strategy.



BIO SERENITY © Cardioskin, in partnership with Servier



BIO SERENITY © A system that allows for home recordings, an app to interact with the patient (eCOA), an expert system with an A.I. assistant. The goal is to reach the right treatment as fast as possible.

Artificial Intelligence at BioSerenity © :  
From diagnosis to prognosis.



Pierre Frouin, CEO and Founder of BioSerenity believes that the success of BioSerenity can be attributed to a combination of factors: *“A number of startups focus on a single technology block whereas BioSerenity has a solution based approach ranging from the capture of data to the analysis in a medical context, this makes us one of the only companies in our domain able to generate the expected medical gains. We have developed an important IP portfolio and we have a top-tier team that collaborates with a large ecosystem. BioSerenity was born in a hospital environment in the Brain and Spine Institute (icm-institute.org) and our pharmaceutical partners appreciate our deep understanding of clinical challenges”*. For Pierre Frouin, *“with this fund raising, we obtain not only the means to finance our growth but also investors who have expertise in the digital and medical innovation, two sectors that intersect at BioSerenity”*

Valéry Huot, Partner and Head of Innovation Capital of LBO France, declares: *“We are glad to bring our support to BioSerenity and its management team. This is the 9th investment of our SISA fund dedicated to innovating companies focused on digital health in Europe. BioSerenity has an impressive track record and we are convinced that the company will continue its high growth. BioSerenity has all the assets to become a major player in bringing solutions for connected patients around the world.”*

Emmanuel Audouard, Director of the PSIM fund at Bpifrance, adds : *“BioSerenity is one of the most promising MedTech companies in its domain. The company brings an innovative solution to diagnostics and monitoring problems. We are glad to support its growth by mobilizing our PSIM fund reserved for winners of the World Wide Innovation Challenge side by side with Idinvest Partners and LBO France.”*

Luc Maruenda, Partner at Idinvest Partners concludes : *“BioSerenity has been executing brilliantly these last two years with the help of a team of 80 dynamic talents and academic, industrial and clinical partners of high quality. We are delighted to renew our trust in the management team of BioSerenity by reinvesting and welcoming new co-investors ”*

#### **About Bioserenity**

BioSerenity, is a company created in 2014 and located inside the ICM Brain and Spine Institute (icm-institute.org) in La Pitié-Salpêtrière hospital, one of the largest and oldest hospitals in Europe. BioSerenity has a shared research lab with the ICM. With over 80 employees, BioSerenity quickly became one of the technology leaders in smart medical solutions for remote monitoring thanks to an integrated network of partners in the hospital, research and pharmaceutical industry. [www.bioserenity.com](http://www.bioserenity.com)

Contact : [corporate@bioserenity.com](mailto:corporate@bioserenity.com) - Téléphone : +33 1 84 25 64 27

#### **About Idinvest Partners**

The mission of Idinvest Partners, a European leader in financing small and medium-sized enterprises, is to fund European businesses at various stages of growth. With more than €8 billion under management, we can harness a range of complementary expertise to help businesses grow quickly using equity and private debt investment, both directly and via private equity funds. Since its formation in 1997, Idinvest has financed more than 3,500 European businesses through its three business lines: Venture & Growth Capital, Private Debt and Private Funds Group. [www.idinvest.com](http://www.idinvest.com)

Contact : Luc Maruenda, Partner, [lm@idinvest.com](mailto:lm@idinvest.com)



### **About LBO France**

As a key player in private equity with €3.6bn of capital under management, LBO France is an independent company which has been supporting French companies in their growth for more than 30 years. Its strategy is based on 4 investment approaches in non-listed companies, managed by dedicated teams: (i) Mid Cap buyout via the White Knight funds and Small Cap buyout via the Hexagone funds, (ii) Venture Capital via the Innovation Capital funds, (iii) Real Estate via the White Stone and Lapillus funds, (iv) Debt. [www.lbofrance.com](http://www.lbofrance.com)

BioSerenity is the 9<sup>th</sup> portfolio company of SISA fund, dedicated to digital healthcare and autonomy, following the investments in Voluntis, FittingBox, Zesty, Wandercraft, Biomodex, H4D, Kayentis and OpenHealth.

Contact : Valery Huot, Partner – Head of Innovation Capital - [valery.huot@lbofrance.com](mailto:valery.huot@lbofrance.com)

Press Contact : Citigate Dewe Rogerson - Robert Amady - +33 6 72 63 08 91 - [robert.amady@citigate.fr](mailto:robert.amady@citigate.fr) / Daiana Hirte - +33 7 60 90 89 12 - [daiana.hirte@citigate.fr](mailto:daiana.hirte@citigate.fr)

### **About Bpifrance**

Bpifrance, a subsidiary of Caisse des Dépôts and the French State, is a trusted partner of entrepreneurs which provides companies with credit, collateral and equity financing support - from start up through to stock exchange listing. In partnership with Business France, Bpifrance also provides guidance and enhanced support services for innovation, external growth, and exports. Bpifrance offers each company a range of financing for each key stage in its development, and an offer adapted to regional particularities. With 48 regional offices (90% of decisions are made regionally), Bpifrance offers entrepreneurs a tool for economic competitiveness. Bpifrance works in support of the public policies pursued nationally and regionally by the French government, to meet three objectives: • support the growth of businesses • prepare for future competitiveness • contribute to the development of an ecosystem that encourages entrepreneurship. With Bpifrance, companies benefit from a strong and effective local contact able to meet all their financial, innovation and investment needs. [www.bpifrance.fr](http://www.bpifrance.fr)

Contact : Nicolas Jehly – [nicolas.jehly@bpifrance.fr](mailto:nicolas.jehly@bpifrance.fr) - +33 1 41 79 95 12